AU2001255798A1 - Glucagon antagonists - Google Patents

Glucagon antagonists

Info

Publication number: AU2001255798A1
Authority: AU; Australia
Prior art keywords: glucagon antagonists; glucagon; antagonists
Prior art date: 2000-05-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2001255798A

Inventor

William S. Marshall

Kevin Lee Stark

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Amgen Inc

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-03

Filing date

2001-05-03

Publication date

2001-11-12

2001-05-03 Application filed by Amgen Inc filed Critical Amgen Inc

2001-11-12 Publication of AU2001255798A1 publication Critical patent/AU2001255798A1/en

Status Abandoned legal-status Critical Current

Links

102000051325 Glucagon Human genes 0.000 title 1
108060003199 Glucagon Proteins 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Endocrinology (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AU2001255798A 2000-05-03 2001-05-03 Glucagon antagonists Abandoned AU2001255798A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US20143600P	2000-05-03	2000-05-03
US60/201,436		2000-05-03
US09/847,249 US6677136B2 (en)	2000-05-03	2001-05-02	Glucagon antagonists
US09/847,249		2001-05-02
PCT/US2001/014321 WO2001083527A2 (en)	2000-05-03	2001-05-03	Glucagon antagonists

Publications (1)

Publication Number	Publication Date
AU2001255798A1 true AU2001255798A1 (en)	2001-11-12

Family

ID=26896746

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2001255798A Abandoned AU2001255798A1 (en)	2000-05-03	2001-05-03	Glucagon antagonists

Country Status (5)

Country	Link
US (1)	US6677136B2 (en)
EP (1)	EP1278772A2 (en)
JP (1)	JP2003531632A (en)
AU (1)	AU2001255798A1 (en)
WO (1)	WO2001083527A2 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7562012B1 (en) *	2000-11-03	2009-07-14	Audible Magic Corporation	Method and apparatus for creating a unique audio signature
CN1774232B (en) *	2002-11-25	2012-05-09	金克克国际有限公司	Skin or hair binding peptides
US20050124550A1 (en) *	2003-06-18	2005-06-09	Peri Krishna G.	Compounds that modulate the glucagon response and uses thereof
MXPA05007210A (en)	2003-11-13	2006-02-10	Hanmi Pharm Ind Co Ltd	Protein complex using immunoglobulin fragment andmethod for the preparation thereof.
US8110665B2 (en)	2003-11-13	2012-02-07	Hanmi Holdings Co., Ltd.	Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
US20050222040A1 (en) *	2004-04-05	2005-10-06	Blm Group, Inc.	Vertebrate peptide modulators of lipid metabolism
US20190330295A1 (en) *	2005-05-04	2019-10-31	Zealand Pharma A/S	Glucagon-like-peptide-2 (glp-2) analogues
CA2628241C (en) *	2005-11-07	2016-02-02	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting physiological solubility and stability
EP2471810A1 (en) *	2006-02-22	2012-07-04	Merck Sharp & Dohme Corporation	Oxyntomodulin derivatives
CA2674354A1 (en)	2007-01-05	2008-07-17	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
GEP20135944B (en) *	2007-02-15	2013-10-25	Indiana Unversity Research And Tech Corporation	Glucagon/glp-1 receptor co-agonists
ES2558155T3 (en) *	2007-10-30	2016-02-02	Indiana University Research And Technology Corporation	Compounds showing glucacon antagonist activity and GLP-1 agonist
AU2008318986B2 (en) *	2007-10-30	2014-12-04	Indiana University Research And Technology Corporation	Glucagon antagonists
CA2713348C (en) *	2008-01-30	2018-10-09	Indiana University Research And Technology Corporation	Ester-based peptide prodrugs
EP2307037A4 (en) *	2008-06-17	2011-08-03	Univ Indiana Res & Tech Corp	GLUCAGON ANALOGUES HAVING PHYSIOLOGICAL PH BUFFERS HAVING ENHANCED SOLUBILITY AND STABILITY
TWI474832B (en)	2008-06-17	2015-03-01	Univ Indiana Res & Tech Corp	Glucagon/glp-1 receptor co-agonists
CN102105159B (en) *	2008-06-17	2015-07-08	印第安纳大学研究及科技有限公司	GIP-based mixed agonists for the treatment of metabolic disorders and obesity
PE20120332A1 (en)	2008-12-19	2012-04-14	Univ Indiana Res & Tech Corp	PEPTIDE PROPHARS FROM THE GLUCAGON SUPERFAMILY BASED ON AMIDA
RU2012101274A (en)	2009-06-16	2013-07-27	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Glucagon Compounds Active Against the GIP Receptor
GB0917072D0 (en) *	2009-09-29	2009-11-11	Univ Ulster	Peptide analogues of glucagon for diabetes therapy
WO2011075393A2 (en)	2009-12-18	2011-06-23	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
MX2012008603A (en)	2010-01-27	2013-01-25	Univ Indiana Res & Tech Corp	Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity.
JP6050746B2 (en)	2010-05-13	2016-12-21	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションIndiana University Research And Technology Corporation	Glucagon superfamily of peptides exhibiting G protein-coupled receptor activity
JP6121323B2 (en)	2010-05-13	2017-05-10	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	Peptides of the glucagon superfamily exhibiting nuclear hormone receptor activity
MX2012014576A (en)	2010-06-24	2013-02-21	Univ Indiana Res & Tech Corp	Amide based glucagon superfamily peptide prodrugs.
CN103458920B (en)	2010-12-22	2016-07-06	印第安那大学科技研究公司	Show the glucagon analogs of GIP receptor active
EP2718318B1 (en)	2011-06-10	2018-07-25	Hanmi Science Co., Ltd.	Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
UA114709C2 (en)	2011-06-17	2017-07-25	Ханмі Сайенс Ко., Лтд.	CONJUGATE CONTAINING OXYNTOMODULIN DERIVATIVES, THE FACILITY OF THE IMMUNOGLOBULIN AND THE NON-REPTIDYL POLYMER, AND ITS APPLICATION
KR20140043793A (en)	2011-06-22	2014-04-10	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	Glucagon/glp-1 receptor co-agonists
SI2723367T1 (en)	2011-06-22	2017-08-31	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
US9944687B2 (en) *	2011-07-04	2018-04-17	Imperial Innovations Limited	Compounds and their effects on feeding behaviour
AU2012325233A1 (en) *	2011-10-21	2014-04-24	Noxxon Pharma Ag	Glucagon binding nucleic acids
MX2014003579A (en)	2011-11-17	2015-04-10	Univ Indiana Res & Tech Corp	Glucagon superfamily peptides exhibiting glucocorticoid receptor activity.
CN104583232B (en)	2012-06-21	2018-04-13	印第安纳大学研究及科技有限公司	Show the glucagon analogs of GIP receptor actives
KR101968344B1 (en)	2012-07-25	2019-04-12	한미약품 주식회사	A composition for treating hyperlipidemia comprising oxyntomodulin analog
SG10201602801YA (en)	2012-11-06	2016-05-30	Hanmi Pharm Ind Co Ltd	Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (en)	2012-11-06	2019-10-01	한미약품 주식회사	A composition for treating diabetes or diabesity comprising oxyntomodulin analog
EP2970511B1 (en)	2013-03-14	2020-09-30	Indiana University Research and Technology Corporation	Insulin-incretin conjugates
TWI802396B (en)	2014-09-16	2023-05-11	南韓商韓美藥品股份有限公司	Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
JP6657230B2 (en)	2014-09-24	2020-03-04	インディアナユニヴァーシティリサーチアンドテクノロジーコーポレイション	Incretin-insulin conjugate
KR102418477B1 (en)	2014-12-30	2022-07-08	한미약품 주식회사	Gluagon Derivatives
TW201639878A (en)	2014-12-30	2016-11-16	韓美藥品股份有限公司	Glycoside derivative with improved stability
HUE066226T2 (en)	2015-06-30	2024-07-28	Hanmi Pharmaceutical Co Ltd	A preparation containing a glucagon derivative and its long-acting conjugate
RS63541B1 (en)	2015-12-31	2022-09-30	Hanmi Pharm Ind Co Ltd	TRIPLE ACTIVATOR THAT ACTIVATES GLUCAGON, GLP-1 AND GIP RECEPTORS
AU2017289014B2 (en)	2016-06-29	2019-12-05	Hanmi Pharm. Co., Ltd.	Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
EP3881861B1 (en)	2017-06-16	2024-07-31	Zealand Pharma A/S	Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
EP3827116A4 (en)	2018-07-23	2022-05-11	The Governors of the University of Alberta	GENETICALLY ENCODED BICYCLIC PEPTIDE LIBRARIES
EP3842061A1 (en) *	2019-12-23	2021-06-30	Merck Sharp & Dohme Corp.	Stapled triazole co-agonists of the glucagon and glp-1 receptors
EP3842449A1 (en) *	2019-12-23	2021-06-30	Merck Sharp & Dohme Corp.	Stapled olefin co-agonists of the glucagon and glp-1 receptors
US20230365623A1 (en) *	2020-09-04	2023-11-16	Florey Institute of Neuroscience and Mental Health	Derivatisation of peptides and proteins

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1023287A (en)	1972-12-08	1977-12-27	Boehringer Mannheim G.M.B.H.	Process for the preparation of carrier-bound proteins
US3941763A (en)	1975-03-28	1976-03-02	American Home Products Corporation	PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en)	1976-05-03	1980-03-25	Bayer Aktiengesellschaft	Polymeric carrier bound ligands
US4330440A (en)	1977-02-08	1982-05-18	Development Finance Corporation Of New Zealand	Activated matrix and method of activation
CA1093991A (en)	1977-02-17	1981-01-20	Hideo Hirohara	Enzyme immobilization with pullulan gel
US4229537A (en)	1978-02-09	1980-10-21	New York University	Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en)	1979-04-06	1981-09-15	Allied Corporation	Macromolecular highly branched homogeneous compound based on lysine units
NL8720442A (en)	1986-08-18	1989-04-03	Clinical Technologies Ass	DELIVERY SYSTEMS FOR PHARMACOLOGICAL AGENTS.
US5229490A (en)	1987-05-06	1993-07-20	The Rockefeller University	Multiple antigen peptide system
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5723286A (en)	1990-06-20	1998-03-03	Affymax Technologies N.V.	Peptide library and screening systems
US5408037A (en)	1991-01-17	1995-04-18	Zymogenetics, Inc.	Methods for detecting glucagon antagonists
US5733731A (en)	1991-10-16	1998-03-31	Affymax Technologies N.V.	Peptide library and screening method
US5270170A (en)	1991-10-16	1993-12-14	Affymax Technologies N.V.	Peptide library and screening method
JPH07505915A (en)	1992-04-14	1995-06-29	コーネル　リサーチ　ファウンデーション、インコーポレーテッド	Dendritic macromolecules and their production method
US5792451A (en)	1994-03-02	1998-08-11	Emisphere Technologies, Inc.	Oral drug delivery compositions and methods
US5349001A (en)	1993-01-19	1994-09-20	Enzon, Inc.	Cyclic imide thione activated polyalkylene oxides
US5922545A (en)	1993-10-29	1999-07-13	Affymax Technologies N.V.	In vitro peptide and antibody display libraries
US5480867A (en)	1993-12-29	1996-01-02	The Rockefeller University	Glucagon analogs with serine replacements
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US6184201B1 (en) *	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6121022A (en) *	1995-04-14	2000-09-19	Genentech, Inc.	Altered polypeptides with increased half-life
US5739277A (en)	1995-04-14	1998-04-14	Genentech Inc.	Altered polypeptides with increased half-life
US6127977A (en)	1996-11-08	2000-10-03	Cohen; Nathan	Microstrip patch antenna with fractal structure
EP0904107B1 (en)	1996-03-18	2004-10-20	Board Of Regents, The University Of Texas System	Immunoglobin-like domains with increased half lives
EP0934526B1 (en)	1996-10-08	2003-01-08	U-BISys B.V.	Methods and means for selecting peptides and proteins having specific affinity for a target
PT954588E (en)	1996-12-20	2007-03-30	Amgen Inc	Ob fusion protein compositions and methods
CA2382165A1 (en) *	1999-12-08	2001-06-14	Genset S.A.	Full-length human cdnas encoding potentially secreted proteins

2001
- 2001-05-02 US US09/847,249 patent/US6677136B2/en not_active Expired - Fee Related
- 2001-05-03 EP EP01929003A patent/EP1278772A2/en not_active Withdrawn
- 2001-05-03 JP JP2001580951A patent/JP2003531632A/en not_active Withdrawn
- 2001-05-03 WO PCT/US2001/014321 patent/WO2001083527A2/en not_active Ceased
- 2001-05-03 AU AU2001255798A patent/AU2001255798A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2003531632A (en)	2003-10-28
WO2001083527A2 (en)	2001-11-08
EP1278772A2 (en)	2003-01-29
US20030032588A1 (en)	2003-02-13
US6677136B2 (en)	2004-01-13
WO2001083527A3 (en)	2002-08-01

Publication	Publication Date	Title
AU2001255798A1 (en)	2001-11-12	Glucagon antagonists
AU2002365622A1 (en)	2003-06-17	Novel glucagon antagonists
AU2002341834A1 (en)	2003-04-07	Antagonists
AU2001274288A1 (en)	2002-01-02	Centraliser
AU2001274302A1 (en)	2002-01-02	Centraliser
DZ3293A1 (en)	2001-08-23	Substituted arylpyrazines
AU2001292739A1 (en)	2002-04-08	1-oxorapamycins
AU2000267458A1 (en)	2001-10-15	Hypercomputer
AU2001254546A1 (en)	2001-11-07	Aminopiperidines
AU6227101A (en)	2001-12-03	Substituted iminoazines
AU2002223501A1 (en)	2002-05-27	Glucagon antagonists/inverse agonists
AU2001220246A1 (en)	2001-12-11	Neckphone
AU2001237637A1 (en)	2001-09-17	Centraliser
AU2001239310A1 (en)	2001-10-03	Decahydro-isoquinolines
AU2001264657A1 (en)	2001-11-26	Crf receptor antagonists
AU2002223500A1 (en)	2002-05-27	Glucagon antagonists/inverse agonists
AU2001234741A1 (en)	2001-08-14	Integrin antagonists
AU2003291959A1 (en)	2004-07-14	Novel glucagon antagonists
AU2001239773A1 (en)	2001-08-27	Baroplastic materials
AU2001265871A1 (en)	2001-11-07	Substituted sulfonylaminopyrimidines
AU2001258255A1 (en)	2001-11-29	Substituted benzoylcyclohexenones
AU5825501A (en)	2001-09-17	Substituted benzoylcyclohexenones
AU2001254731A1 (en)	2001-10-23	Substituted phenyluracils
AU2001276354A1 (en)	2002-03-14	Hetaryl-substituted heterocycles
AU2001271018A1 (en)	2002-01-14	Gpr14 antagonist